The US FDA has sent a warning letter to CRO Drug Research and Analysis Corp. founder and president Henry Frazer for failing to adhere to the agency’s regulations governing clinical trials.
The US Food and Drug Administration (FDA) can require opioid generics to have abuse-deterrent properties if the same requirements are applicable to their brand name counterparts, FDA Commissioner Margaret Hamburg said in a letter to Rep. Fred Upton (R-Mich.)...
IntelliPharmaCeutics is ready to move into full-scale clinical
trials with a once-daily oral formulation of oxycodone based on the
company's ReXista abuse- and alcohol-resistant technology.
A novel painkiller in development at Pain Therapeutics - based on a
technology that both improves dosing and prevents drug abuse - has
done well in a Phase III clinical trial.
